Details of the Drug

General Information of Drug (ID: DMJSFTX)

Drug Name

CPI-006

Indication

Disease Entry	ICD 11	Status	REF
Advanced cancer	2A00-2F9Z	Phase 1	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]
------------------------------------------------------------------------------------

Drug Type

Antibody

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Advanced cancer

ICD Disease Classification

2A00-2F9Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Ecto-5'-nucleotidase (CD73)	DTT	NT5E	9.56E-01	0.33	0.37

Molecular Expression Atlas (MEA)

Jump to Detail Molecular Expression Atlas of This Drug

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	ClinicalTrials.gov (NCT03454451) CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers. U.S. National Institutes of Health.
3	Clinical pipeline report, company report or official report of Corvus Pharmaceuticals.